Aleve Challenge, New Study Catch Up To Advil ‘Works Longer’ Claim In NAD Review

摘要

E vidence that supports making a drug available OTC in the US isn’t the fnal word on marketing claims for the ingredient, a Council of Better Bureaus’ industry self-regulation arm con- cluded in a review of Aleve marketer Bayer AG’s challenge to Pfzer Inc.’s advertising for Advil. A report published 10 September by the National Advertising Division of the council’s BBB National Programs Inc. also states that while Pfzer criticized the inpatient methodology of the study Bayer submitted to support its challenge, inpatient is the industry standard for pain medication trials.